Ma JG - Search Results

1

[Androgen receptor mutation and progression of prostate cancer].

Ma JG, Li WP, Jiang YQ. Ma JG, et al. Zhonghua Nan Ke Xue. 2011 Jul;17(7):649-54. Zhonghua Nan Ke Xue. 2011. PMID: 21823352 Review. Chinese.

2

Downregulation of protocadherin-10 expression correlates with malignant behaviour and poor prognosis in human bladder cancer.

Ma JG, He ZK, Ma JH, Li WP, Sun G. Ma JG, et al. Among authors: ma jh. J Int Med Res. 2013 Feb;41(1):38-47. doi: 10.1177/0300060513476989. Epub 2013 Jan 23. J Int Med Res. 2013. PMID: 23569128 Free article.

3

Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer.

Wang L, Lin YL, Li B, Wang YZ, Li WP, Ma JG. Wang L, et al. Among authors: ma jg. J Int Med Res. 2014 Oct;42(5):1085-92. doi: 10.1177/0300060514540631. Epub 2014 Jul 11. J Int Med Res. 2014. PMID: 25015764 Free article.

4

Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy.

Wang L, Xie PG, Lin YL, Ma JG, Li WP. Wang L, et al. Among authors: ma jg. Med Sci Monit. 2014 Aug 3;20:1363-8. doi: 10.12659/MSM.891241. Med Sci Monit. 2014. PMID: 25086586 Free PMC article.

5

Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy.

Lin YL, Xie PG, Wang L, Ma JG. Lin YL, et al. Among authors: ma jg. Med Sci Monit. 2014 Aug 5;20:1376-82. doi: 10.12659/MSM.891247. Med Sci Monit. 2014. PMID: 25091018 Free PMC article.

6

Aberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer.

Lin YL, Xie PG, Ma JG. Lin YL, et al. Among authors: ma jg. Med Sci Monit. 2014 Sep 4;20:1572-7. doi: 10.12659/MSM.892130. Med Sci Monit. 2014. PMID: 25196672 Free PMC article.

7

Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer.

Niu WB, Gui SL, Lin YL, Fu XL, Ma JG, Li WP. Niu WB, et al. Among authors: ma jg. Med Sci Monit. 2014 Dec 8;20:2584-9. doi: 10.12659/MSM.893083. Med Sci Monit. 2014. PMID: 25486497 Free PMC article.

8

Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.

Lin YL, Wang YL, Ma JG, Li WP. Lin YL, et al. Among authors: ma jg. J Exp Clin Cancer Res. 2014 Aug 22;33(1):68. doi: 10.1186/s13046-014-0068-7. J Exp Clin Cancer Res. 2014. PMID: 25927589 Free PMC article.

9

Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.

Lin YL, Gui SL, Guo H, Ma JG, Li WP. Lin YL, et al. Among authors: ma jg. Med Sci Monit. 2015 Sep 25;21:2870-6. doi: 10.12659/MSM.895603. Med Sci Monit. 2015. PMID: 26404644 Free PMC article.

10

Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy.

Lin YL, Deng QK, Wang YH, Fu XL, Ma JG, Li WP. Lin YL, et al. Among authors: ma jg. Med Sci Monit. 2015 Dec 19;21:3955-690. doi: 10.12659/msm.896763. Med Sci Monit. 2015. PMID: 26683656 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

205 results

Search Page

Filters